Jump to content
RemedySpot.com

Why us with SPMS need LDN

Rate this topic


Guest guest

Recommended Posts

So this just made the news but then we knew it all along right?

Reg

Data Do Not Support Use Of Intravenous Immunglobulin G In Patients With Secondary Progressive MS

A group of European researchers said recent findings do not support the use of intravenous immunoglobulin G (IVIG) as a treatment for patients with secondary progressive MS.

In the study, 318 patients with secondary progressive MS received IVIG or a placebo once a month for 27 months. The researchers monitored how much time passed until patients in each group experienced treatment failure.

Complete data were available for 280 patients at 27 months. Treatment failure occurred in 77 patients in the IVIG and 70 patients in the placebo group. Patients in the IVIG group were 11 percent more likely to fail treatment than patients receiving placebo.

There was also no significant difference in the annual relapse rate (0.46 percent for both groups).

Moreover, patients treated with IVIG also had a higher rate of deep venous thrombosis, which may suggest some potential risks associated with this treatment, the authors of the study commented.

”In the light of the many encouraging results with this treatment in earlier stages of the disease, however, these negative findings should not discourage further investigations into the mechanisms of action of IVIG to avoid missing the chance of a potentially useful therapy in relapsing-remitting MS,” the investigators concluded.

This research was published in the Sept. 25 issue of The Lancet.

--------------------------------------------------------------------------------

A complimentary medical news service provided by Teva Neuroscience, this news service has been developed independently and does not necessarily reflect the opinions of Teva Neuroscience. MS Update is a current news service provided by FAXWATCH™. The staff of medical writers at FAXWATCH™ independently summarize and abstract the most current articles on subjects in multiple sclerosis from the major peer-reviewed medical publications, such as ls of Neurology, JAMA, New England Journal of Medicine and Journal of Neurology. In all cases, FAXWATCH™ cites the original source of its material.

____________________________________________________ IncrediMail - Email has finally evolved - Click Here

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...